Storia in 2 fonti

Why Merck Just Slashed Its Profit Outlook By Nearly 50% - Merck & Co (NYSE:MRK)

Merck cuts FY2026 adjusted EPS outlook nearly in half to $2.66-$2.76, citing $2.43/share in charges from its Terns acquisition.

Raccontata da

cnbc.com

benzinga.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

benzinga.comStai leggendo13 h fa

Why Merck Just Slashed Its Profit Outlook By Nearly 50% - Merck & Co (NYSE:MRK)

Merck cut 2026 EPS 47% due to $5.93/share acquisition charges, yet beat Q2 revenue ($16.61B, +5%) and raised FY revenue guidance. Keytruda and Animal Health perform strongly; M&A from Cidara and Terns signals pharma consolidation in biotech innovation space.

originale

cnbc.com21 h fa

Merck hikes revenue outlook as new drug sales grow, but cuts profit guidance due to deal charges

Merck cut its profit guidance due to a charge tied to its acquisition of biotech company Terns Pharmaceuticals.

Leggi questa versione → originale

Timeline cronologica

martedì 4 agosto 2026·cnbc.com
Merck hikes revenue outlook as new drug sales grow, but cuts profit guidance due to deal charges
Merck cut its profit guidance due to a charge tied to its acquisition of biotech company Terns Pharmaceuticals.
martedì 4 agosto 2026·benzinga.com
Why Merck Just Slashed Its Profit Outlook By Nearly 50% - Merck & Co (NYSE:MRK)
Merck cuts FY2026 adjusted EPS outlook nearly in half to $2.66-$2.76, citing $2.43/share in charges from its Terns acquisition.